PR Newswire

Tue Jan 11

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

Written by PR Newswire Asia - News Pronto RSS

Study to evaluate ATG-101, a proprietary PD-L1/4-1BB bispecific antibody

Study will enroll patients with Metastatic/Advanced Solid Tumors and Mature B-Cell Non-Hodgkin Lymphomas

SHANGHAI AND HONG KONG, Dec. 20, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company...

PR Newswire

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

More Articles ...

Crime and punishment must keep up with the Information Economy

As many Muslims return to mosques today, they will need ongoing support

What Are Immigrants Rights?

Wild Butterfly film review: Claire Murray's story gives a human face to trauma, drug use and blame culture

Panic attacks aren't necessarily a reason to panic: they are your body's way of responding to stress

Trauma, resilience, sex and art: your guide to the 2020 Miles Franklin shortlist

How New Zealanders miss out on hundreds of thousands in retirement savings

With Cohen and Manafort both guilty, the pressure on Trump is rising

First stage of 'road back' will boost monthly GDP by $3.1 billion and jobs by 252,500: Frydenberg

How much physical activity should teenagers do, and how can they get enough?

Where did you grow up? How strontium in your teeth can help answer that question